Lipid Disorders
Latest News
Bariatric surgery still best option for some with obesity
“Sometimes we might need to go straight to surgery instead of going through medications first, because it may be the most effective and evidence-...
Latest News
PREVENT: AHA’s new risk calculator incorporates CKM health
PREVENT is for use in adults aged 30-79 years and estimates the 10- and 30-year risk of total CVD including, for the first time, heart failure.
Conference Coverage
Promising first results with DNA editing to lower LDL
The first in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial...
Conference Coverage
Pharmacist-based strategy places more patients on statins
In two studies run in parallel fashion, testing different strategies, automatic referral to a pharmacist was superior to EHR alerts for increasing...
Conference Coverage
Sustained reductions in Lp(a) achieved with novel siRNA drug
“At the highest doses, lepodisiran is not just lowering Lp(a), it appears to be getting rid of it.”
Feature
How to prescribe exercise in 5 steps
“The most important thing to know about exercise is that finding the time and having the health to do so is a privilege.”
Latest News
Gaps persist in awareness, treatment of high LDL cholesterol
Among people with the higher LDL-C level, one in four are both unaware and untreated.
From the Journals
Another study ties statins to T2D: Should practice change?
“When using rosuvastatin over atorvastatin, we ... emphasize the importance of meticulous monitoring and appropriate lifestyle interventions to...
Latest News
High and low HDL cholesterol levels linked to dementia risk
There was no significant association between LDL cholesterol and dementia risk.
From the Journals
LDL cholesterol lowering tied to less risk of first CVD events in patients older than 70
Any potential benefits should be balanced against potential harms in this population, as these individuals may have comorbidities and may be...
Conference Coverage
Muvalaplin and olpasiran show early promise in lowering Lp(a)
“For the first time we have an oral agent” that lowers Lp(a) levels. However, “we will still need to determine if this leads to a reduction in...